# Madhuveer Com 18 Network share price (Madhuveer Com 18 Network Ltd, NSE: MADHUVEER)

> Madhuveer Com 18 Network share price: ₹228.00 at the NSE close on 6 March 2026, the latest close in our records; down 8.2% in the year to that date. Madhuveer Com 18 Network (NSE: MADHUVEER) is worth ₹581 crore, trades at a P/E of 660.0 and has closed between ₹160.50 and ₹281.25 over the past 52 weeks. > Madhuveer Com 18 Network Ltd's share price has risen faster than its earnings: −8.2% in a year, against −127.5% for earnings per share. MADHUVEER · Pharma - Others · data as of 6 March 2026. Page: https://www.sectoralpha.in/stocks/madhuveer-com-18-network-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹228.00 (−8.2% in a year)
- P/E: 660.0× (higher than 72% of the last 8.7 years)
- Revenue (Dec 2025): ₹8.2 Cr (+257.5% on a year ago)
- Profit (Dec 2025): ₹1.0 Cr (+3.0% on a year ago)
- Operating margin: 69.7% (+18.4 points on a year ago)
- ROCE: −1%, FY25

The main question: profits are rising, but only −34% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Madhuveer Com 18 Network share price? Madhuveer Com 18 Network Ltd's share price was ₹228.00 at the close on 6 March 2026. It has been rising for 10 weeks. That is 2.3% above its average price over the last 200 trading days. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 13 weeks in a row. In the last 52 weeks it traded between ₹161 and ₹281, and at that close it sat 56% of the way up from that low. Over the last 10 years the share price moved +5,658% while the NIFTY 500 moved +260%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Madhuveer Com 18 Network this quarter? 3 points in one quarter and highest quarterly revenue in 13 quarters. 1. Best operating margin in 12 quarters Operating margin was 69.7% in the December 2025 quarter, against 51.3% a year earlier. 2. Promoters raised their stake by 1.3 points in one quarter From 66.5% to 67.8% in the December 2025 quarter. 3. Highest quarterly revenue in 13 quarters Revenue of ₹8 crore in the December 2025 quarter is the highest of the last 13 quarters. ## What are Madhuveer Com 18 Network's latest quarterly results? For October to December 2025 (the quarter ended 31 December 2025), Madhuveer Com 18 Network reported revenue of ₹8.15 crore, up 257.5% from ₹2.28 crore a year earlier, and a profit of ₹1.02 crore, up 3.0% from ₹0.99 crore. ### Madhuveer Com 18 Network results: October to December 2025 against a year earlier

| Measure | October to December 2025 | October to December 2024 | Change |
| --- | --- | --- | --- |
| Revenue | ₹8.15 crore | ₹2.28 crore | +257.5% |
| Profit | ₹1.02 crore | ₹0.99 crore | +3.0% |
| Earnings per share | ₹0.40 | ₹0.40 | 0.0% |
| Operating margin | 69.7% | 51.3% | +18.4 points |

The next results, for January to March 2026, are due by 30 May 2026: listed companies must publish quarterly results within 60 days of the quarter's end (the January to March quarter comes with the full-year accounts). (From the company's reported quarterly results (quarter ended 31 December 2025). Revenue and profit in ₹ crore.)

## What is the Madhuveer Com 18 Network share price history? Madhuveer Com 18 Network closed at ₹228.00 on 6 March 2026, down 8.2% from ₹248.40 a year earlier (7 March 2025) and up 9,561.0% over five years. Its highest weekly close since March 2016 was ₹297.35 on 27 December 2024. ### Madhuveer Com 18 Network share price: then and now

| When | Close | Change to 6 Mar 2026 |
| --- | --- | --- |
| 1 week ago · 27 Feb 2026 | ₹253.55 | −10.1% |
| 1 month ago · 6 Feb 2026 | ₹261.65 | −12.9% |
| 6 months ago · 5 Sep 2025 | ₹235.80 | −3.3% |
| 1 year ago · 7 Mar 2025 | ₹248.40 | −8.2% |
| 3 years ago · 3 Mar 2023 | ₹11.35 | +1,908.8% |
| 5 years ago · 24 Feb 2021 | ₹2.36 | +9,561.0% |
| 10 years ago · 10 Mar 2016 | ₹3.96 | +5,657.6% |
| Earliest weekly close in our records · 10 Mar 2016 | ₹3.96 | +5,657.6% |
| Highest weekly close since March 2016 · 27 Dec 2024 | ₹297.35 | −23.3% |
| Lowest weekly close since March 2016 · 22 Nov 2017 | ₹1.06 | +21,409.4% |
| 52-week high (weekly close) · 2 Jan 2026 | ₹281.25 | −18.9% |
| 52-week low (weekly close) · 8 Aug 2025 | ₹160.50 | +42.1% |

Weekly closing prices. Each change is the move from that price to the 6 Mar 2026 close. A day's intraday high or low can go beyond these weekly closes. (277 weekly closes from 10 March 2016 to 6 March 2026.)

## What is the latest news on Madhuveer Com 18 Network? 6 Mar 2026: Madhuveer Com 18 Network closed at ₹228.00, down 10.1% on the week and down 12.9% on the month. Results for October to December 2025: Revenue up 257.5% and profit up 3.0% on a year earlier. ## What dividend does Madhuveer Com 18 Network pay? Madhuveer Com 18 Network has paid no dividend on the NSE since 1 April 2021, the start of the period we checked. No. Madhuveer Com 18 Network Ltd paid out 0% of its profit as dividends in each of its last 8 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 4 November 2026.)

## Which stock lists is Madhuveer Com 18 Network on? Madhuveer Com 18 Network is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 581](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Madhuveer Com 18 Network profitable? Madhuveer Com 18 Network Ltd earned ₹1.0 Cr of net profit in the Dec 2025 quarter, +3.0% on the same quarter a year earlier. The full FY25 year was a loss of ₹1.7 Cr. That is 12.5% of the quarter's revenue. The same quarter a year earlier earned ₹1.0 Cr. 5 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was −₹1.7 Cr (−170.9% on the year before). ## How much revenue does Madhuveer Com 18 Network make, and is it growing? Madhuveer Com 18 Network Ltd reported ₹8.2 Cr of revenue in the Dec 2025 quarter, +257.5% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 8 years it has grown 55.2% a year on average. The last full year, FY25, came in at ₹4.4 Cr. The last four reported quarters add to ₹12.8 Cr. FY25 revenue was ₹4.4 Cr, −8.9% on the year before. Recent pace: the last four quarters grew +1,173.3% on average, against 55.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +68.7%, against +701.2% a year over the last 8 quarters (rolling over). ## How much of every ₹100 of sales does Madhuveer Com 18 Network keep? Madhuveer Com 18 Network Ltd's operating margin was 69.7% in the Dec 2025 quarter, 18.4 percentage points higher than the same quarter a year ago. Across 8 years it has been between −400.0% and 40.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +18.4 percentage points on the year while gross margin changed +0.0 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Madhuveer Com 18 Network's profit turning into cash? Over the last 3 years Madhuveer Com 18 Network Ltd's operations used more cash than they brought in, so cash conversion was −34%, a gap worth watching. In FY25 its operations used ₹12.9 Cr of cash, against −₹1.7 Cr of profit. After ₹7.0 Cr of spending on assets, free cash was −₹20.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Madhuveer Com 18 Network's cash go? Madhuveer Com 18 Network Ltd's customer, stock and supplier day counts come out in the thousands of days on sales this small (₹4.4 Cr in FY25), so no cash-cycle chart is drawn and this section looks at its spending on assets instead. It spent ₹22.0 Cr on assets over the last 3 years. Averaged over those years that is 167.4% of FY25 revenue a year. Spending on assets: ₹22.0 Cr over the last 3 years, against ₹2.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹3.1 Cr (FY25): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Madhuveer Com 18 Network's P/E ratio, and how does it compare with its own history? Madhuveer Com 18 Network Ltd's P/E is 660.0×, near the high end of its own history: higher than 72% of past readings. Its usual P/E (the middle reading) is 150.0×, over 8.7 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Dec 2025 add up to ₹0.33. Why the multiple is where it is: over the past year earnings per share moved −127.5% while the price moved −8.2%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved +171.8% a year; about +224.0% a year came from earnings growth and about −52.2 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Madhuveer Com 18 Network business getting better or worse? Madhuveer Com 18 Network Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Madhuveer Com 18 Network earn on its capital? Madhuveer Com 18 Network Ltd earned a ROCE of −1% in FY25. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a −37.9% net margin and 0.08× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −37.9% net margin × 0.08× asset turnover × 1.24× leverage (assets divided by equity) ≈ −3.8% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. ## Does Madhuveer Com 18 Network have too much debt? Madhuveer Com 18 Network Ltd had ₹6.5 Cr of borrowings against ₹42.5 Cr of equity in FY25, so its debt is 0.15× its equity. Its operating profit is −8 times its interest bill. Over 5 years borrowings went from ₹0.1 Cr to ₹6.5 Cr. Over the last 3 of those years it spent ₹22.0 Cr on assets. Part of the spending on assets is being paid for with borrowed money. ## What is the Madhuveer Com 18 Network shareholding pattern? Promoters raised their stake in Madhuveer Com 18 Network Ltd by 63.9 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 67.8% of the company. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Why the owners changed: promoters drove it (+63.9 points). They raised their stake step by step. ## How far is Madhuveer Com 18 Network from balance-sheet trouble? For Madhuveer Com 18 Network Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Madhuveer Com 18 Network rank in its industry? 42.8 out of 100, rank 10 of 10 in Pharma - Others, with 33% of the evidence available. It is provisional, so it is ranked below companies with full evidence. Madhuveer Com 18 Network Ltd scores 42.8 out of 100 against the 10 companies it is compared with in Pharma - Others, ranking 10. Some evidence is missing, so the score is pulled toward the middle on purpose. The three scored parts add up to the total exactly: 20.5 + 11.7 + 10.6 = 42.8 (no relative-strength reading this week; its 20 points are shared across the other three). This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Madhuveer Com 18 Network compared with? Madhuveer Com 18 Network ranks 10 of 10 Pharma - Others companies on the 4-Factor Sector Score, with 42.8 out of 100. 1. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) SYNCOMF · breaking out · Most evidence points up · 89% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.4/35 · Revenue 0.4% · Profit 48.3% · Operating margin change 7 points · 88% evidence Capital efficiency 17.2/25 · ROCE 24.7% · Operating margin 21% · 100% evidence Valuation 15.1/20 · P/E 21.2× · PEG 0.79 · 65% evidence Relative strength 17.8/20 · Lead over its industry -0.2% · Lead over NIFTY 500 32.3% · 1 year 16.7% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.4 + 17.2 + 15.1 + 17.8 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Shukra Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/shukra-pharmaceuticals-ltd) SHUKRAPHAR · breaking out · Too little evidence to rank firmly · 56% evidence 69.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.5/35 · Revenue 100% · Profit 100% · Operating margin change 66 points · 83% evidence Capital efficiency 19.4/25 · ROCE 37% · Operating margin 90% · 76% evidence Valuation 9.3/20 · P/E 91.9× · PEG n/a · 15% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 83.7% · 1 year 82.8% · 25% evidence · 6 of 6 weeks ahead Exact sum: 28.5 + 19.4 + 9.3 + 12.5 = 69.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 3. [Sun Pharma Advanced Research Company Ltd](https://www.sectoralpha.in/stocks/sun-pharma-advanced-research-company-ltd) SPARC · quiet · Evidence leans up · 78% evidence 61.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 100% · Profit 100% · Operating margin change 455 points · 65% evidence Capital efficiency 16.0/25 · ROCE 164% · Operating margin -85% · 100% evidence Valuation 15.0/20 · P/E 3.6× · PEG n/a · 50% evidence Relative strength 4.3/20 · Lead over its industry -17.4% · Lead over NIFTY 500 9.3% · 1 year 30.9% · 100% evidence · 1 of 12 weeks ahead Exact sum: 25.8 + 16 + 15 + 4.3 = 61.1 · What this means: Earnings are strong; relative strength in its sector is -17.4% and the one-year return is 30.9%. 4. [Remus Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/remus-pharmaceuticals-ltd) REMUS · breaking out · Too little evidence to rank firmly · 54% evidence 54.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.5/35 · Revenue 57.3% · Profit 80% · Operating margin change -4 points · 27% evidence Capital efficiency 13.3/25 · ROCE 11.5% · Operating margin 32% · 57% evidence Valuation 11.2/20 · P/E 41.2× · PEG n/a · 50% evidence Relative strength 12.8/20 · Lead over its industry -12.6% · Lead over NIFTY 500 16.6% · 1 year 17.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 17.5 + 13.3 + 11.2 + 12.8 = 54.8 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) TTKHLTCARE · quiet · Evidence leans up · 85% evidence 50.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.8/35 · Revenue 11.3% · Profit 100% · Operating margin change -1 points · 100% evidence Capital efficiency 6.8/25 · ROCE 8% · Operating margin 1.6% · 100% evidence Valuation 15.7/20 · P/E 17.6× · PEG 1.38 · 100% evidence Relative strength 8.4/20 · Lead over its industry n/a · Lead over NIFTY 500 -3% · 1 year -23.1% · 25% evidence · 10 of 12 weeks ahead Exact sum: 19.8 + 6.8 + 15.7 + 8.4 = 50.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Unichem Laboratories Ltd](https://www.sectoralpha.in/stocks/unichem-laboratories-ltd) UNICHEMLAB · losing its lead · Evidence leans down · 64% evidence 38.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.4/35 · Revenue 7.2% · Profit 100% · Operating margin change 6.7 points · 62% evidence Capital efficiency 6.6/25 · ROCE 4.1% · Operating margin 11% · 76% evidence Valuation 10.0/20 · P/E 27.9× · PEG n/a · 15% evidence Relative strength 8.3/20 · Lead over its industry -13.3% · Lead over NIFTY 500 15.4% · 1 year 2.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 13.4 + 6.6 + 10 + 8.3 = 38.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) PANACEABIO · basing · Most evidence points down · 76% evidence 20.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 8.2/35 · Revenue 10.3% · Profit -80% · Operating margin change 3.5 points · 88% evidence Capital efficiency 1.2/25 · ROCE -2.4% · Operating margin 2.8% · 100% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 1.0/20 · Lead over its industry -38.3% · Lead over NIFTY 500 -16.4% · 1 year -28.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 8.2 + 1.2 + 10 + 1 = 20.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) leader · Too little evidence to rank firmly · 48% evidence 61.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.1/43.75 · Revenue 100% · Profit 100% · Operating margin change 53.1 points · 62% evidence Capital efficiency 19.4/31.25 · ROCE 16.8% · Operating margin 44.7% · 95% evidence Valuation 11.1/25 · P/E 219× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.1 + 19.4 + 11.1 = 61.6 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Jenburkt Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jenburkt-pharmaceuticals-ltd) Too little evidence to rank firmly · 47% evidence 56.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.6/43.75 · Revenue 11.8% · Profit 6.1% · Operating margin change 6 points · 53% evidence Capital efficiency 21.8/31.25 · ROCE 27.2% · Operating margin 32% · 71% evidence Valuation 14.3/25 · P/E 13.2× · PEG n/a · 50% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.6 + 21.8 + 14.3 = 56.7 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 10. Madhuveer Com 18 Network Ltd this page MADHUVEER · Too little evidence to rank firmly · 33% evidence 42.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.5/43.75 · Revenue 68.7% · Profit 12.8% · Operating margin change 18.4 points · 45% evidence Capital efficiency 11.7/31.25 · ROCE -1.1% · Operating margin 69.7% · 57% evidence Valuation 10.6/25 · P/E 660× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 20.5 + 11.7 + 10.6 = 42.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Others](https://www.sectoralpha.in/sectors/pharma-others), all 10 compared on one page. ## Which companies are close to Madhuveer Com 18 Network in size? Madhuveer Com 18 Network is the 9th largest of 10 Pharma - Others companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Panacea Biotec, Syncom Formulations (India), JOJO, TTK Healthcare and Remus Pharmaceuticals. Just below it: Jenburkt Pharmaceuticals. ### Pharma - Others companies close in size

1. [Panacea Biotec Ltd](https://www.sectoralpha.in/stocks/panacea-biotec-ltd) ₹1,919 crore
2. [Syncom Formulations (India) Ltd](https://www.sectoralpha.in/stocks/syncom-formulations-indialtd) ₹1,809 crore
3. [JOJO Ltd](https://www.sectoralpha.in/stocks/jojo-ltd) ₹1,539 crore
4. [TTK Healthcare Ltd](https://www.sectoralpha.in/stocks/ttk-healthcare-ltd) ₹1,279 crore
5. [Remus Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/remus-pharmaceuticals-ltd) ₹994 crore
6. Madhuveer Com 18 Network Ltd ₹581 crore
7. [Jenburkt Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/jenburkt-pharmaceuticals-ltd) ₹498 crore

[All 10 Pharma - Others companies, largest first](https://www.sectoralpha.in/sectors/pharma-others#all-companies)

### Companies close in size in other industries

1. [Satani Bearings Ltd](https://www.sectoralpha.in/stocks/satani-bearings-ltd) ₹582 crore · Trading
2. [Indef Manufacturing Ltd](https://www.sectoralpha.in/stocks/indef-manufacturing-ltd) ₹581 crore · Engineering - Heavy - Material Handling
3. Madhuveer Com 18 Network Ltd ₹581 crore
4. [Shri Jagdamba Polymers Ltd](https://www.sectoralpha.in/stocks/shri-jagdamba-polymers-ltd) ₹581 crore · Textiles - Technical Textile
5. [Heranba Industries Ltd](https://www.sectoralpha.in/stocks/heranba-industries-ltd) ₹580 crore · Pesticides/Agrochemicals

## What else do people ask about Madhuveer Com 18 Network? ### What were Madhuveer Com 18 Network's latest quarterly results? Madhuveer Com 18 Network Ltd reported revenue of ₹8.2 Cr and net profit of ₹1.0 Cr for the Dec 2025 quarter. Revenue rose 257.5% and profit rose 3.0% compared with a year earlier. Earnings per share were ₹0.40 (as of 6 March 2026). ### What is Madhuveer Com 18 Network's market cap? Madhuveer Com 18 Network Ltd's market capitalisation is ₹581 Cr at a share price of ₹228.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 6 March 2026). ### How is Madhuveer Com 18 Network performing? Madhuveer Com 18 Network Ltd's share price has been rising for 10 weeks. In its latest quarter, revenue rose 257.5% and profit rose 3.0% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 13 weeks running (as of 6 March 2026). ### Will Madhuveer Com 18 Network's share price go up? This page does not forecast Madhuveer Com 18 Network Ltd's share price. What it shows instead: the share price is ₹228.00, and it has been rising for 10 weeks. Its P/E of 660.0× is higher than 72% of its own last 9 years (as of 6 March 2026). ### Where is Madhuveer Com 18 Network in its business cycle? Madhuveer Com 18 Network Ltd's FY25 operating margin was −17.4%, against a 8-year range of −400.0% to 40.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 69.7%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 6 March 2026). ### What could break the Madhuveer Com 18 Network story? The main question: profits are rising, but only −34% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 6 March 2026). ### Is Madhuveer Com 18 Network a stock worth studying right now? What the numbers show: Madhuveer Com 18 Network Ltd's share price has risen faster than its earnings: −8.2% in a year, against −127.5% for earnings per share. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 6 March 2026). ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.